Klampenborg, Denmark

Søren Peter Olesen

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.4

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2005-2010

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Søren Peter Olesen

Introduction

Søren Peter Olesen is a notable inventor based in Klampenborg, Denmark. He has made significant contributions to the field of medical technology, particularly in the treatment of cardiac arrhythmias. With a total of three patents to his name, Olesen's work has the potential to impact patient care and therapeutic approaches.

Latest Patents

Olesen's latest patents include innovative solutions for medical treatments. One of his key inventions is related to ERG channel openers for the treatment of cardiac arrhythmias. This invention focuses on the use of specific compounds that serve as ERG channel openers, providing new avenues for treatment. Another significant patent involves benzimidazol-2-one derivatives, which are useful as therapeutic agents. These compounds are designed to enhance blood-brain barrier permeability, offering potential benefits in various medical applications.

Career Highlights

Throughout his career, Olesen has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable organizations include Neurosearch A/S and Poseidon Pharmaceuticals A/S. His experience in these companies has allowed him to develop and refine his innovative ideas, contributing to advancements in medical treatments.

Collaborations

Olesen has collaborated with several professionals in his field, including Palle Christophersen and Bo Skaaning Jensen. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his inventions.

Conclusion

Søren Peter Olesen's contributions to medical technology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of cardiac conditions and therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…